...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Translational Research >Effect of combined application of iguratimod in the treatment of active rheumatoid arthritis on bone metabolism, Th17 cells and Treg cells
【24h】

Effect of combined application of iguratimod in the treatment of active rheumatoid arthritis on bone metabolism, Th17 cells and Treg cells

机译：Iguratimod在骨代谢，Th17细胞和Treg细胞中治疗活性类风湿性关节炎治疗活性类风湿性关节炎的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: This study was designed to analyse the effect of combined application of iguratimod with methotrexate in the treatment of active rheumatoid arthritis (RA). Methods: A total of 115 patients with active RA admitted to our hospital were enrolled and divided into group A (n=58) and group B (n=57) according to the method of random number table. Patients in group B were treated with methotrexate alone, while patients in group A were treated with methotrexate combined with iguratimod. The curative efficacy was compared between the two groups. Results: At 6 months after treatment, the levels of CTX-1 and RANKL in group A were higher than those in group B, and the levels of OPG, IL-17 and TGF-α in group A were lower than those in group B ( P 0.05). The level of Th17 cells in group A was higher than that in group B, and the level of Treg cells in group A was lower than that in group B at 6 months after treatment ( P 0.05). Tender joints count, swollen joints count and DAS28 score in group A were less than those in group B at 6 months after treatment ( P 0.05). The duration of morning stiffness of the joints and the score of joint pain degree in group A were less than those in group B at 1, 2, 3, 4, 5, and 6 months after treatment ( P 0.05). Conclusion: The combined application of methotrexate and iguratimod in the treatment of active RA can effectively improve bone metabolism, regulate the levels of Th17 and Treg cells, play a prominent role in anti-inflammatory effect, and relieve symptoms, and thus achieve a more satisfactory curative effect.
机译：目的：本研究旨在分析Iguratimod与甲氨蝶呤在治疗活性类风湿性关节炎（RA）中的甲氨蝶呤综合应用的影响。方法：根据随机数表的方法，共注册并分为对我们医院的115例活性RA患者，并分为A（n = 58）和B组（n = 57）。 B组患者单独用甲氨蝶呤治疗，而A组患者均用甲氨蝶呤与IGURATIMOD联系。在两组之间比较疗效。结果：治疗后6个月，A组CTX-1和RANK1的水平高于B组，A组A中的OPG，IL-17和TGF-α水平低于B组（P <0.05）。 A组中Th17细胞的水平高于B组中的细胞，A组中的Treg细胞水平低于处理后6个月的B组（P <0.05）。招标关节计数，A组肿胀的关节计数和DAS​​28分数在治疗后6个月内少于B组（P <0.05）。关节的早晨刚度的持续时间和A组关节疼痛程度的分数小于在处理后1,2,3,4,5和6个月内的B组（P <0.05）。结论：甲氨蝶呤和Iguratimod在活性RA治疗中的综合应用可以有效改善骨代谢，调节Th17和Treg细胞的水平，在抗炎作用中发挥着突出作用，并缓解症状，从而实现更令人满意的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号